Lake Street Maintains Buy on Cellebrite DI, Lowers Price Target to $15
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $21 to $15.
Economy · News reference
US stocks up, Dow gains over 100 points. Real estate sector rises, energy sector falls. Producer Price Index unchanged, inflation rate down.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Lake Street analyst Eric Martinuzzi maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $21 to $15.
JP Morgan analyst Brian Essex maintains Cellebrite DI (NASDAQ:CLBT) with a Overweight and lowers the price target from $20 to $16.
DA Davidson analyst Rudy Kessinger maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $22 to $15.
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $15 to $12.5.
Gainers Xos (NASDAQ:XOS) shares rose 82.8% to $3.82 during Monday's after-market session. The company's market cap stands at $29.7 million. The company's, Q2 earnings came out 2 days ago. Wetour Robotics